Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders.

In 2007, he became the Dean of the School and Executive Vice President for Academic Affairs of what was then known as the Mount Sinai Medical Center.

[10] Charney led the Mood and Anxiety Research Program at the National Institute of Mental Health and earlier was on the faculty in the department of psychiatry at Yale Medical School.

[4] According to published works, Charney's research is centered around various fields such as psychiatry, anesthesia, clinical psychology, and major depressive disorder.

In recognition of his significant contributions to new treatments for mood and anxiety disorders, including the use of ketamine for resistant depression, Charney received the Donald Klein Lifetime Achievement Award from the American Society for Psychopharmacology in 2023.

[16] Traumatic stress, anxiety and neuroscience[17] is part of his psychology study and is frequently connected to suicide prevention, bridging the gap between various science disciplines and establishing new relationships.

[18][19][20][21] Charney owns patents in dopamine and noradrenergic reuptake inhibitors in the treatment of schizophrenia[22] and in intranasal administration of ketamine to treat depression.

[54] He has been named among the top 3 most highly cited authors of psychiatric research in the decade ending in 2000 by the Institute for Scientific Information.